ST
ACAD icon

Spot Trading’s Acadia Pharmaceuticals ACAD Stock Holding History

Spot Trading’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-7,500
Closed -$210K – 3262
2016
Q1 		$210K Buy
7,500
+6,600
+733% +$144K ﹤0.01% 2180
2015
Q4 		$32K Sell
900
-2,400
-73% -$84.6K ﹤0.01% 3150
2015
Q3 		$109K Buy
3,300
+1,300
+65% +$54.1K ﹤0.01% 3006
2015
Q2 		$84K Buy
2,000
+800
+67% +$31K ﹤0.01% 3146
2015
Q1 		$39K Sell
1,200
-54,900
-98% -$1.89M ﹤0.01% 3360
2014
Q4 		$1.78M Buy
56,100
+35,400
+171% +$1M 0.01% 1479
2014
Q3 		$513K Buy
20,700
+13,100
+172% +$306K ﹤0.01% 2540
2014
Q2 		$172K Hold
7,600
– – ﹤0.01% 3429
2014
Q1 		$185K Sell
7,600
-14,800
-66% -$374K ﹤0.01% 3175
2013
Q4 		$560K Sell
22,400
-36,800
-62% -$868K ﹤0.01% 2394
2013
Q3 		$1.63M Sell
59,200
-32,100
-35% -$671K 0.01% 1546
2013
Q2 		$1.66M Buy
+91,300
New +$1.26M 0.01% 1525

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

Spot Trading's ACAD Position: Q4 2016 in Review

Spot Trading sold out of Acadia Pharmaceuticals (ACAD) in Q4 2016, closing a stake of 7,701 shares — an estimated $204K sold.

Spot Trading first reported a position in ACAD in Q2 2013 and held it in 13 quarters. The position peaked at $513K in Q2 2013. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • Spot Trading reported no remaining Acadia Pharmaceuticals position as of Q4 2016 after selling out during the quarter.
  • Spot Trading sold 7,701 Acadia Pharmaceuticals shares in Q4 2016, an estimated $204K.
  • Spot Trading first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 13 quarters.
  • Spot Trading's Acadia Pharmaceuticals position peaked at $513K in Q2 2013.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on Spot Trading's 13F filing for Q4 2016, filed 7 Feb 2017.